Valvular & structural heart disease
Redo–Transcatheter Aortic Valve Replacement With Self-Expanding Valves: A U.S. Registry Analysis
Authors' conclusion
In a national registry, redo-TAVR with the Evolut platform was associated with low procedural complication rates and clinical outcomes comparable with those observed with native TAVR.
Study context
- Population
- Patients undergoing TAVR with self-expanding Evolut valves in the STS/ACC TVT Registry
- Exposure
- Redo-TAVR vs native TAVR with self-expanding Evolut valves
- Redo-TAVRn = 439
- Outcome
- All-cause mortality, stroke and readmission
- Follow-up
- 30 days and 1 year
Methodological detailsnational registry, adjusted comparison
- National registry
- Adjusted comparison
Main finding
As reported in the abstract
Redo-TAVR vs Native TAVRAdjusted hazard ratio (95% CI)P value
Mortality, 30 days
0.66(0.39–1.13)
P = 0.129Stroke, 30 days
0.95(0.54–1.68)
P = 0.853Readmission, 30 days
0.88(0.65–1.20)
P = 0.422Mortality, 1 year
0.91(0.72–1.15)
P = 0.441Stroke, 1 year
0.91(0.63–1.34)
P = 0.644Readmission, 1 year
0.92(0.76–1.13)
P = 0.439Observational data: associations, not effects.
Further findings
Transvalvular gradient · 1 year
P < 0.001
Functional status and quality of life after redo-TAVR · through 1 year
- Improvements observed early and sustained through 1 year
Prespecified subgroups
- Findings consistent across prespecified subgroups
Safety
Procedural complications (redo-TAVR)
- Procedural complication rates were low
Original publication
Redo–Transcatheter Aortic Valve Replacement With Self-Expanding Valves: A U.S. Registry Analysis. JACC Cardiovasc Interv. Published 24 August 2026. doi:10.
Summarised from the published abstract; every number is checked against it